BIONTECH SE use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech's Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC's website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law. Pfizer Contacts: Media Relations Amy Rose +1 (212) 733-7410 https://www.globenewswire.com/Tracker?data=mwe6FB9G6Spnm7OBiJnc7yM_lk6XJ1FuO2b5lOxNp6dAq0jGdWLrsSaoPkptJUxTZ88qD_Q1lUInHKnOwzynoJGee4oNOznS4M5oVb5uxiw= Amy.Rose@pfizer.com Investor Relations Chuck Triano +1 (212) 733-3901 https://www.globenewswire.com/Tracker?data=g8hgyv1f3kkfcVFE4zXiTVQnttHdKQQZaejBd2WrykvoO2on6bDX1Eu3UDQw3CGt3BdV5OvOykRM9slTh4XKcBvbRjOI0CSYcDUK2nMCRjDHZu8fkvJ4WUo3yz2k9R6j Charles.E.Triano@Pfizer.com BioNTech Contacts: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 https://www.globenewswire.com/Tracker?data=6XRPXw5UDURM1pRLELnAE4ZOk7Wzs_M-TnvEhVJIzx_j8mBv5Vyzq3oDHhMQD11N3cvoSR1oEWxwhcJ6HopDELTyiG46UxePwGtNHV9Tln4= Media@biontech.de Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 https://www.globenewswire.com/Tracker?data=jxZvQJwryYIaHHZgiUItaYz5VVJ5wcMHqUEmhyRsuHv7UYUSPyAMnsZnTyoF2uGl9F9iMmXCnS1h3_bMNfQw6YLyF-K982e694JljCGV_z0= Investors@biontech.de
(END) Dow Jones Newswires
May 06, 2021 06:30 ET (10:30 GMT)
